Yunxiao Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yunxiao Zhu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Daisy Lopez
CellTrans Inc. Chicago Illinois USA
1 shared publication - David G. Cook
CellTrans Inc., Chicago, IL 60612, USA
1 shared publication - Guillermo Antonio Ameer
Department of Biomedical Engineering, Northwestern University, Evanston, IL, 60208, USA
1 shared publication - Hafsa Nasir
CellTrans Inc. Chicago Illinois USA
1 shared publication - Ira Joshi
CellTrans Inc. Chicago Illinois USA
1 shared publication - Jacqueline A. Burke
Northwestern University
1 shared publication
Latest Publications
- Open Access
- 7 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (23) , eadk3081
Phase-changing citrate macromolecule combats oxidative pancreatic islet damage, enables islet engraftment and function in the omentum
Clinical outcomes for total-pancreatectomy followed by intraportal islet autotransplantation (TP-IAT) to treat chronic pancreatitis (CP) are suboptimal due to pancreas inflammation, oxidative stress during islet isolation, and harsh engraftment conditions in the liver’s vasculature. We describe a thermoresponsive, antioxidant macromolecule poly(polyethylene glycol citrate- co - N -isopropylacrylamide) (PPCN) to protect islet redox status and function and to enable extrahepatic omentum islet engraftment. PPCN solution transitions from a liquid to a hydrogel at body temperature. Islets entrapped in PPCN and exposed to oxidative stress remain functional and support long-term euglycemia, in contrast to islets entrapped in a plasma-thrombin biologic scaffold. In the nonhuman primate (NHP) omentum, PPCN is well-tolerated and mostly resorbed without fibrosis at 3 months after implantation. In NHPs, autologous omentum islet transplantation using PPCN restores normoglycemia with minimal exogenous insulin requirements for >100 days. This preclinical study supports TP-IAT with PPCN in patients with CP and highlights antioxidant properties as a mechanism for islet function preservation.
- 7 June 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (23) , eadk3081
Open AccessPhase-changing citrate macromolecule combats oxidative pancreatic islet damage, enables islet engraftment and function in the omentum
Clinical outcomes for total-pancreatectomy followed by intraportal islet autotransplantation (TP-IAT) to treat chronic pancreatitis (CP) are suboptimal due to pancreas inflammation, oxidative stress during islet isolation, and harsh engraftment conditions in the liver’s vasculature. We describe a thermoresponsive, antioxidant macromolecule poly(polyethylene glycol citrate- co - N -isopropylacrylamide) (PPCN) to protect islet redox status and function and to enable extrahepatic omentum islet engraftment. PPCN solution transitions from a liquid to a hydrogel at body temperature. Islets entrapped in PPCN and exposed to oxidative stress remain functional and support long-term euglycemia, in contrast to islets entrapped in a plasma-thrombin biologic scaffold. In the nonhuman primate (NHP) omentum, PPCN is well-tolerated and mostly resorbed without fibrosis at 3 months after implantation. In NHPs, autologous omentum islet transplantation using PPCN restores normoglycemia with minimal exogenous insulin requirements for >100 days. This preclinical study supports TP-IAT with PPCN in patients with CP and highlights antioxidant properties as a mechanism for islet function preservation.